Dual antisense oligonucleotide targeting miR-21/miR-155 synergize photodynamic therapy to treat triple-negative breast cancer and inhibit metastasis

Biomed Pharmacother. 2022 Feb:146:112564. doi: 10.1016/j.biopha.2021.112564. Epub 2021 Dec 23.

Abstract

Triple negative breast cancer (TNBC) is a greatly aggressive subtype of breast cancer with high recurrence and mortality rates. Chemotherapy as a primary treatment for cancer is limited due to toxic side effects and drug resistance. Therefore, low toxicity and more effective breast cancer therapeutic approaches are greatly desired. In this study, a strategy which using ZIF-90 nanoparticles co-deliver Ce6-anti-miR-21 and Ce6-anti-miR-155 into the tumor cells was developed. Due to the pH responsive drug release of ZIF-90, antisense oligonucleotides (anti-miRNAs) and photosensitizers are able to be efficiently released inside tumor microenvironment. The nano delivery system captures overexpressed oncogenic miRNAs while the photosensitizer Ce6 generates ROS under light irradiation to effectively induce the apoptosis of tumor cell. This combinatorial effect was verified by results showing that the purposed therapic method could effectively inhibit tumor cell proliferation and metastasis. The concept of antisense oligonucleotide combined with photodynamic therapy has great potential in cancer treatment or adjuvant therapy.

Keywords: Photodynamic therapy; Synergistic therapy; Triple negative breast cancer; ZIF-90; miRNA.

MeSH terms

  • Cell Line
  • Cell Proliferation / drug effects
  • Drug Liberation
  • Humans
  • Hydrogen-Ion Concentration
  • MicroRNAs* / drug effects
  • Nanoparticle Drug Delivery System
  • Neoplasm Metastasis
  • Oligonucleotides, Antisense* / pharmacology
  • Particle Size
  • Photochemotherapy* / methods
  • Photosensitizing Agents* / pharmacology
  • Surface Properties
  • Triple Negative Breast Neoplasms* / pathology

Substances

  • MicroRNAs
  • MIRN155 microRNA, human
  • MIRN21 microRNA, human
  • Nanoparticle Drug Delivery System
  • Oligonucleotides, Antisense
  • Photosensitizing Agents
  • ZIF-90